Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.79 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL552436 | 0.89 | TAAR1 (1.00) | TAAR1SIGMAR1PYCR1 | |
| Hydrochloric Acid SCHEMBL7966176 | 0.87 | TAAR1 (0.96) | TAAR1SIGMAR1PYCR1 | |
| SCHEMBL18762842 | 0.86 | SIGMAR1 (0.61) | TAAR1SIGMAR1NOS3NOS1 | |
| SCHEMBL5240585 | 0.82 | TAAR1 (0.68) | TAAR1SIGMAR1 | |
| SCHEMBL9670825 | 0.80 | SIGMAR1 (0.70) | TAAR1SIGMAR1NOS3NOS1 | |
| SCHEMBL19524669 | 0.80 | TAAR1 (0.65) | TAAR1SIGMAR1 | |
| SCHEMBL15564078 | 0.79 | NOS3 (0.56) | TAAR1SIGMAR1NOS3NOS1 | |
| SCHEMBL417687 | 0.79 | TAAR1 (0.59) | TAAR1SIGMAR1 | |
| SCHEMBL11300491 | 0.78 | TAAR1 (0.79) | TAAR1SIGMAR1NOS3NOS1PYCR1 | |
| SCHEMBL5336469 | 0.78 | DRD2 (0.57) | TAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TAAR1 555/4885SIGMAR1 98/4885HTR6 1081/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | TAAR1 295/4885SIGMAR1 28/4885HTR6 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.